Rapid uptake of GLP‑1 receptor agonists such as semaglutide and tirzepatide is shifting clinical practice: prescriptions have surged among patients eligible for metabolic and bariatric surgery, and surgical volumes are declining in several centers as pharmaceutical options expand. The shift is already changing referral patterns and capacity planning in bariatric surgery programs. Regulators moved to curb unapproved, compounded copies of GLP‑1 drugs: the FDA issued a new wave of warning letters to telehealth and compounding firms for marketing compounded products with misleading claims. Commissioner Marty Makary signaled intensified enforcement against firms claiming parity with approved branded medicines. The combined clinical and regulatory actions are forcing payers, health systems, and device/surgical vendors to retool assumptions about long‑term demand and safety oversight in obesity and metabolic care.